The relationship between monocyte/HDL cholesterol ratio and chronic kidney disease stages, single center study

Abstract

Objectives: Chronic kidney disease (CKD) is an increasing public health problem. It is very important to know the definition of CKD, its risk factors and to predict the progression of its stages. Recently, the monocyte/HDL ratio (MHR) has been thought to be a new marker of inflammation and oxidative stress. In this study, it was aimed to investigate the relationship between stages and MHR in patients with stage 3A, stage 3B and stage 4 CKD. Methods: A total of 632 patients with CKD, aged 18 years and older, with stage 3A, stage 3B and stage 4 (eGFR) according to CKD stage were included in our study. Our study is retrospective and the data of the patients were obtained from the hospital system. Kruskal-Wallis and post hoc Tukey HSD tests were used for statistics. p < 0.05 was considered statistically significant. Results: The mean age of the patients included in the study was 63.4 ± 14.91(min:18max:98), and 305 (48.25%) of these patients were male and 327 (51.75%) were female. According to eGFR, 155 (24.5%) of the patients were stage 3A, 150 (23.8%) were stage 3B, and 327 (51.7%) were stage 4. In the statistical study of the groups divided into CKD stages with MHR, there was no significant difference between the groups (p: 0.245), while there was statistical significance for gender and hypertension (p: 0.004 and p: 0.044, respectively). Conclusion: As a result of this study, we concluded that MHR is not affected by CKD stages.